Cytovance offers licenses for plasmid DNA tech

By The Science Advisory Board staff writers

March 8, 2021 -- Contract development and manufacturing organization (CDMO) Cytovance Biologics is offering a new licensing opportunity for gene therapy plasmid DNA (pDNA) manufacturing.

The company's Keystone Expression System pDNA platform is an end-to-end solution for manufacturing good manufacturing practice (GMP) pDNA at scale in a manufacturer's own facility. The platform is designed to process plasmids with low-shear lysis and purification steps. The system can reduce the time and cost of producing pDNA-based products, according to the company.

License opportunities are currently available for either 30- or 300-L manufacturing scales. Each license includes end-to-end documentation including process descriptions, analytical standard operating procedures, critical equipment lists, and facility layout. Cytovance is also offering hands-on process training at manufacturing facilities.

Cas9 modification can improve efficiency of gene editing
A modification to CRISPR/Cas9 systems can improve their functionality for gene editing in DNA repair, according to a report published in Nature Communications...
AGC Biologics expands plasmid manufacturing capacity
AGC Biologics is expanding its plasmid DNA Center of Excellence in Heidelberg, Germany, to meet the need for process development and manufacturing of...

Copyright © 2021

BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter